PTX3 and breast cancer: As shown in Figure 1B,C, 100% of low-grade BC samples were strongly positive for PTX3 immunoreactivity, whereas 47% of high-grade NMIBCs were characterized by a lower/mild immunoreactivity, and 62.5% of high-grade muscle invasive BC samples showed a low (37.5%) or absent (25%) PTX3 positivity.